title: [Study of the bactericidal effect of cefpodoxime using an in vitro pharmacokinetic model].
abstract: Cefpodoxime is a new oral prodrug antibiotic. Following absorption from the proximal intestine, non-specific esterases hydrolyze this cleavable ester, releasing cefpodoxime, a new broad-spectrum third-generation cephalosporin with sustained plasma levels in humans. Cefpodoxime killing kinetics were studied using an in vitro model which simulates the pharmacokinetic profile obtained in healthy volunteers given a single oral dose of cefpodoxime proxetil providing 100, 200 or 400 mg active cefpodoxime. Cefpodoxime exhibited strong antibacterial activity against tested strains of Escherichia coli, Streptococcus pneumoniae and Staphylococcus aureus. These results suggest that use of two daily doses of 100 or 200 mg each are appropriate for the treatment of E. coli and S. pneumoniae infections in view of the pharmacokinetic properties of cefpodoxime. Less intensive therapy is probably adequate in uncomplicated community-acquired urinary tract infections. The bactericidal effect of cefpodoxime against S. aureus is prolonged due to a postantibiotic effect.
authors.affiliation: Centre de Recherche Roussel-Uclaf, Romainville, France.
authors.forename: A
authors.initials: A
authors.lastname: Caisson
authors.forename: J F
authors.initials: JF
authors.lastname: Chantot
mesh_terms: D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000187:drug effects*; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests / Q000379:methods*; D011355:Prodrugs / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D000097627:Cefpodoxime Proxetil
chemical_list: D015296:Ceftizoxime; D011355:Prodrugs; D000097627:Cefpodoxime Proxetil
vernacular_title: Etude de l'activité bactéricide du cefpodoxime par modélisation pharmacocinétique in vitro.